Fraunhofer Sputum Core Facility

Fraunhofer ITEM's sputum center

Custom-tailored study design for your sputum analysis

We assist you in the selection of specific sputum biomarkers.
© Fraunhofer ITEM
We assist you in the selection of specific sputum biomarkers.

Our experienced sputum center offers centralized organization and analysis to achieve optimal results for sputum analysis in multicenter clinical trials. We guarantee the best choice of sputum methodology to meet the requirements of a particular trial. Furthermore, we offer study-specific training for our clients, supervision of quality during study conduct, and analysis of a broad spectrum of biomarkers.

Services and equipment for sputum analysis

Track Record and equipment

Scientific staff with many years of experience

Over 30 papers and reviews on methods of sputum analysis and their use

Consultancy to pharmaceutical industry in non-invasive airway monitoring

Member of the sputum taskforce

Training for multicenter trials involving sputum analyses since 2001

Experienced team of study nurses and technical staff

Numerous clinical trials with sputum analysis

Routine performance of sputum induction

Sputum induction and processing according to SOPs

Comprehensive experience with client-specific sputum protocols

Method development and validation of new biomarkers incl. chip cytometry

GCP compliance


Sputum taskforce document

Paggiaro PL, Chanez P, Holz O, Ind PW, Djukanović R, Maestrelli P, Sterk PJ. Sputum induction. Eur Respir J Suppl. 2002

Sputum quality

Frauke Pedersen, Ulrich M. Zissler, Henrik Watz, Klaus F. Rabe, Jens M. HohlfeldOlaf Holz. Rating sputum cell quality in clinical trials for asthma and COPD treatment. Int. Journal of COPD, 2019

Clinical trials with sputum analysis

Holz O, Biller H, Mueller M, Kane K, Rosano M, Hanrahan J, Hava DL, Hohlfeld JM. Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model—a clinical trial. BMC Pharmacol Toxicol. 2015

Janssen O, Schaumann F, Holz O, Lavae-Mokhtari B, Welker L, Winkler C, Biller H, Krug N, Hohlfeld JM. Low-dose endotoxin inhalation in healthy volunteers—a challenge model for early clinical drug development. BMC Pulm Med. 2013

Röpcke S, Holz O, Lauer G, Müller M, Rittinghausen S, Ernst P, Lahu G, Elmlinger M, Krug N, Hohlfeld JM. Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum. PLoS One. 2012; 7 (10)

Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni P, Tsai M, Sadeh J, Magnussen H. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J. 2010

Sputum methodology and challenge studies

Biller H, Holz O, Windt H, Koch W, Müller M, Jörres RA, Krug N, Hohlfeld JM. Breath profiles by electronic nose correlate with systemic markers but not ozone response. Respir Med. 2011

Holz O, Tal-Singer R, Kanniess F, Simpson KJ, Gibson A, Vessey RS, Janicki S, Magnussen H, Jörres RA, Richter K. Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development. J Clin Pharmacol. 2005 May; 45 (5): 498-503. PubMed PMID: 15831772

Holz O, Mücke M, Paasch K, Böhme S, Timm P, Richter K, Magnussen H, Jörres RA. Repeated ozone exposures enhance bronchial allergen responses in subjects with rhinitis or asthma. Clin Exp Allergy. 2002